YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) (ContraFect), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that on May 16, 2022, the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock option awards to purchase an aggregate of 15,000 shares of its common stock to two new non-executive employees.
Read more at globenewswire.comContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here